Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome

Therapeutic Drug Monitoring

Volumn 22, Issue 3, 2000, Pages 366-368

  Dilger, Karin ^a   Meisel, Peter ^b   Hofmann, Ute ^a   Eichelbaum, Michel ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

CYP2D6; Gilbert's syndrome; Propafenone

Indexed keywords

CLOFIBRATE; DEBRISOQUINE 4 HYDROXYLASE; GLUCURONOSYLTRANSFERASE; JOSAMYCIN; LAMOTRIGINE; LORAZEPAM; NICOTINIC ACID; PROPAFENONE; RIFAMPICIN; RIFAMYCIN; TOLBUTAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG LABELING; DRUG METABOLISM; ENZYME DEFICIENCY; FEMALE; GILBERT DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; RADIOISOTOPE DIAGNOSIS; URINARY EXCRETION;

ADULT; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; PROPAFENONE;

EID: 0034120105     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200006000-00020     Document Type: Article

References (14)

1. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiar-rhythmic drugs. Br J Clin Pharmacol 1998;46:307-19.
2. Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 1984:54:9D-12D.
3. Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med 1990;322:518-25.
4. Siddoway LA, Thompson KA, McAllister CB et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
5. Bosma PJ, Chowdhoury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
6. De Morais SMF, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992;102:577-86.
7. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolisers of CYP2D6. Pharmacogenetics 1999;9:551-9.
8. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578-81.
9. Kutz K, Schulte A, Jensen C, Gugler R. Impaired drug conjugation in subjects with Gilbert's syndrome. Gastroenterology 1977;73: A1229.
10. Okolicsanyi L, Venuti M, Strazzabosco M et al. Pharmacokinetics of josamycin in patients with liver cirrhosis and Gilbert's syndrome after repeated doses. Int J Clin Pharmacol Ther 1985;23: 434-8.
11. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br J Clin Pharmacol 1989;28:117-20.
12. Herman RJ, Chaudhary A, Szakacs CB. Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding and enterohepatic circulation. J Clin Pharmacol 1994;34:978-84.
13. Gentile S, Marmo R, Persico M, Bronzino P, Coltorti M. Impaired plasma clearance of nicotinic acid and rifamycin-SV in Gilbert's syndrome: evidence of a functional heterogeneity. Hepatogastroenterology 1985;32:113-6.
14. Carulli N, Ponz de Leon M, Mauro E, Manenti F, Ferrari A. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976;17: 581-7.